Clinical Trials · NCT06937086
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 350
- Start date
- Jun 2025
- Locations
- 189 sites, 23 countries
- Primary endpoint
- Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction